Camurus AB (publ) (CAMRF)
USD 59.98
(0.01%)
USD 59.98
(0.01%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 1.71 Billion SEK | 79.52% |
| 2022 | 956.34 Million SEK | 59.24% |
| 2021 | 600.57 Million SEK | 78.74% |
| 2020 | 335.99 Million SEK | 218.16% |
| 2019 | 105.6 Million SEK | 114.12% |
| 2018 | 49.32 Million SEK | -9.18% |
| 2017 | 54.3 Million SEK | -52.25% |
| 2016 | 113.73 Million SEK | -26.53% |
| 2015 | 154.79 Million SEK | -25.65% |
| 2014 | 208.2 Million SEK | 5.31% |
| 2013 | 197.71 Million SEK | 107.68% |
| 2012 | 95.2 Million SEK | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 444.86 Million SEK | 14.07% |
| 2024 Q1 | 389.98 Million SEK | 4.12% |
| 2023 Q3 | 383.98 Million SEK | -43.05% |
| 2023 FY | 1.71 Billion SEK | 79.52% |
| 2023 Q4 | 374.56 Million SEK | -2.45% |
| 2023 Q2 | 674.26 Million SEK | 137.39% |
| 2023 Q1 | 284.03 Million SEK | 5.98% |
| 2022 Q1 | 220.28 Million SEK | 20.51% |
| 2022 FY | 956.34 Million SEK | 59.24% |
| 2022 Q3 | 241.36 Million SEK | 6.48% |
| 2022 Q4 | 268.01 Million SEK | 11.04% |
| 2022 Q2 | 226.68 Million SEK | 2.91% |
| 2021 Q3 | 153.98 Million SEK | 11.67% |
| 2021 Q4 | 182.79 Million SEK | 18.71% |
| 2021 FY | 600.57 Million SEK | 78.74% |
| 2021 Q1 | 125.89 Million SEK | 19.26% |
| 2021 Q2 | 137.89 Million SEK | 9.53% |
| 2020 Q1 | 49.29 Million SEK | 40.75% |
| 2020 FY | 335.99 Million SEK | 218.16% |
| 2020 Q4 | 105.56 Million SEK | 5.3% |
| 2020 Q3 | 100.26 Million SEK | 23.97% |
| 2020 Q2 | 80.87 Million SEK | 64.05% |
| 2019 Q4 | 35.02 Million SEK | -12.82% |
| 2019 Q1 | 18.49 Million SEK | 136.95% |
| 2019 Q2 | 11.91 Million SEK | -35.58% |
| 2019 Q3 | 40.17 Million SEK | 237.24% |
| 2019 FY | 105.6 Million SEK | 114.12% |
| 2018 Q2 | 7.31 Million SEK | -50.03% |
| 2018 FY | 49.32 Million SEK | -9.18% |
| 2018 Q4 | 7.8 Million SEK | -60.1% |
| 2018 Q3 | 19.56 Million SEK | 167.42% |
| 2018 Q1 | 14.63 Million SEK | 168.21% |
| 2017 FY | 54.3 Million SEK | -52.25% |
| 2017 Q3 | 12.52 Million SEK | -34.58% |
| 2017 Q4 | 5.45 Million SEK | -56.41% |
| 2017 Q1 | 17.19 Million SEK | -53.69% |
| 2017 Q2 | 19.13 Million SEK | 11.32% |
| 2016 Q1 | 20.24 Million SEK | -44.29% |
| 2016 FY | 113.73 Million SEK | -26.53% |
| 2016 Q3 | 30.53 Million SEK | 18.18% |
| 2016 Q4 | 37.12 Million SEK | 21.6% |
| 2016 Q2 | 25.83 Million SEK | 27.6% |
| 2015 Q2 | 22.65 Million SEK | -61.31% |
| 2015 Q1 | 58.56 Million SEK | -59.57% |
| 2015 Q3 | 37.23 Million SEK | 64.31% |
| 2015 Q4 | 36.34 Million SEK | -2.4% |
| 2015 FY | 154.79 Million SEK | -25.65% |
| 2014 Q4 | 144.87 Million SEK | 326.21% |
| 2014 Q3 | 33.99 Million SEK | 0.0% |
| 2014 FY | 208.2 Million SEK | 5.31% |
| 2013 FY | 197.71 Million SEK | 107.68% |
| 2012 FY | 95.2 Million SEK | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Evofem Biosciences, Inc. | 18.21 Million USD | -9323.921% |
| Arch Therapeutics, Inc. | 75.72 Thousand USD | -2267146.844% |
| CSL Limited | 14.69 Billion USD | 88.313% |
| Santhera Pharmaceuticals Holding AG | 122.95 Million USD | -1296.337% |
| Regen BioPharma, Inc. | 236.56 Thousand USD | -725656.679% |
| BioStem Technologies, Inc. | 16.68 Million USD | -10189.531% |
| Capstone Therapeutics Corp. | 48.35 Million USD | -3450.585% |
| Qrons Inc. | - USD | -Infinity% |
| Nascent Biotech, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 1.93 Million USD | -88763.872% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | -2452542.857% |
| Skye Bioscience, Inc. | - USD | -Infinity% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | 658.5 Thousand USD | -260621.336% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Genscript Biotech Corporation | 839.52 Million USD | -104.502% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| Eiger BioPharmaceuticals, Inc. | 15.77 Million USD | -10784.74% |
| Nanobac Pharmaceuticals, Incorporated | 17.62 Thousand USD | -9743104.131% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| SQZ Biotechnologies Company | 21.47 Million USD | -7893.528% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | -2611952.702% |
| Propanc Biopharma, Inc. | - USD | -Infinity% |
| Mesoblast Limited | 5.9 Million USD | -28989.292% |
| Marizyme, Inc. | 645.81 Thousand USD | -265744.443% |
| Genus plc | 668.8 Million USD | -156.706% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| Pharming Group N.V. | 245.31 Million USD | -599.852% |
| Therapeutic Solutions International, Inc. | 98.99 Thousand USD | -1734197.028% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | -418475.451% |
| Nymox Pharmaceutical Corporation | - USD | -Infinity% |
| ContraFect Corporation | - USD | -Infinity% |
| PsyBio Therapeutics Corp. | - USD | -Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | -2236517.553% |
| IMV Inc. | - USD | -Infinity% |
| AXIM Biotechnologies, Inc. | 39.51 Thousand USD | -4344375.935% |
| MultiCell Technologies, Inc. | 49.32 USD | -3481042073.56% |
| ONE Bio Corp. | 52.29 Million USD | -3182.934% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 49.72 Million USD | -3352.968% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 48.9 Thousand USD | -3510840.695% |
| Q BioMed Inc. | 284.35 Thousand USD | -603676.305% |
| Emmaus Life Sciences, Inc. | 29.59 Million USD | -5700.757% |
| Mosaic ImmunoEngineering Inc. | - USD | -Infinity% |
| Biomind Labs Inc. | - USD | -Infinity% |
| American Oriental Bioengineering, Inc. | 145.09 Million USD | -1083.222% |
| Provectus Biopharmaceuticals, Inc. | 557.71 Thousand USD | -307739.2% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | - USD | -Infinity% |
| Curative Biotechnology, Inc. | - USD | -Infinity% |
| GB Sciences, Inc. | - USD | -Infinity% |
| Alpha Cognition Inc. | - USD | -Infinity% |
| HST Global, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Halberd Corporation | 999.00 USD | -171856756.857% |
| Enzolytics Inc. | 52.79 Thousand USD | -3251756.201% |
| Agentix Corp. | - USD | -Infinity% |
| Resverlogix Corp. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 608.52 Thousand USD | -282033.027% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.22 Billion USD | -40.001% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | 140.24 Thousand USD | -1224105.302% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | -277984.628% |
| Zenith Capital Corp. | - USD | -Infinity% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | - USD | -Infinity% |
| WPD Pharmaceuticals Inc. | - USD | -Infinity% |
| Cotinga Pharmaceuticals Inc. | - USD | -Infinity% |
| Kadimastem Ltd | - USD | -Infinity% |
| Helix BioMedix, Inc. | 997.72 Thousand USD | -171976.302% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | - USD | -Infinity% |
| LadRx Corporation | - USD | -Infinity% |
| Cell Source, Inc. | - USD | -Infinity% |
| Regen BioPharma, Inc. | 236.56 Thousand USD | -725656.679% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Affymax, Inc. | 1.36 Million USD | -125309.058% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| CytoDyn Inc. | - USD | -Infinity% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 473.73 Thousand USD | -362311.078% |
| SYBLEU INC | 11.69 Thousand USD | -14678850.068% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | -Infinity% |
| International Stem Cell Corporation | 7.78 Million USD | -21941.982% |
| Bioxytran, Inc. | - USD | -Infinity% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 13 Thousand USD | -13206438.462% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | - USD | -Infinity% |
| Neutra Corp. | 39.53 Thousand USD | -4342617.661% |
| Windtree Therapeutics, Inc. | - USD | -Infinity% |
| PureTech Health plc | 3.33 Million USD | -51457.057% |
| Coeptis Therapeutics, Inc. | - USD | -Infinity% |
| IXICO plc | 6.66 Million USD | -25659.19% |
| IntelGenx Technologies Corp. | 1.03 Million USD | -165140.616% |
| Gelesis Holdings, Inc. | 25.76 Million USD | -6562.98% |
| CSL Limited | 14.8 Billion USD | 88.4% |
| Cellectis S.A. | 755 Thousand USD | -227297.351% |